This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: Annals of Thoracic Surgery
Author(s): Damien J. LaPar, Ivan K. Crosby, Irving L. Kron, John A. Kern, Edwin Fonner, Jeffrey B. Rich, Alan M. Speir, Gorav Ailawadi

In the US, preoperative beta-blockade is a hospital quality metric that must be addressed at the time of each operation.  This study reviewed STS Database data for isolated CABG in nearly 44,000 pts.  After risk adjustment, beta-blockade had no effect on mortality, morbidity, or hospital resource utilization.  The authors suggest that beta-blockade is not a useful quality metric for CABG. 

Source: Seminars in Thoracic and Cardiovascular Surgery
Author(s): GE Darling, NK Altorki, JD Luketich, MB Orringer

This article is a transcription of a roundtable discussion on surgical management of esophageal cancer involving recognized experts in the field.  Topics include conduit preparation, pyloric drainage, conduit preconditioning, postoperative reflux, the role of surgery in multimodality therapy, and the choice of incisions for esophagectomy.

Source: Annals of Oncology
Author(s): A. Suzuki, L. Xiao, T. Taketa, K. Sudo, R. Wadhwa, M. A. Blum, H. Skinner, R. Komaki, B. Weston, J. H. Lee, M. S. Bhutani, D. C. Rice, D. M. Maru, J. Erasmus, S. G. Swisher, W. L. Hofstetter, and J. A. Ajani

This single-center study analyzed outcomes for 323 pts with esophageal adenocarcinoma who achieved a clinical CR after chemoradiotherapy to determine the prognostic value of pretreatment PET.  Patients with an SUV >6 faired better with induction therapy and resection compared to definitive chemoradiotherapy.  Those with an SUV <6 did equally well with either treatment regimen.  PET SUV may facilitate determining whether bimodality or trimodality is optimal for patients with esophageal adenocarcinoma. 

Source: New England Journal of Medicine
Author(s): Philippe Gabriel Steg, Arnoud van 't Hof, Christian W. Hamm, Peter Clemmensen, Frédéric Lapostolle, Pierre Coste, Jurrien Ten Berg, Pierre Van Grunsven, Gerrit Jan Eggink, Lutz Nibbe, Uwe Zeymer, Marco Campo dell' Orto, Holger Nef, Jacob Steinmetz, Louis Soulat, Kurt Huber, Efthymios N. Deliargyris, Debra Bernstein, Diana Schuette, Jayne Prats, Tim Clayton, Stuart Pocock, Martial Hamon, and Patrick Goldstein for the EUROMAX Investigators

This trial of 2218 pts with STEMI being transported for PCI randomized pts to bivalirudin or standard therapy (LMW heparin with optional glycoprotein IIb/IIIa inhibitors).  The primary outcome was death or major bleeding.   Bivalirudin was associated with a significant reduction (40%) in the primary outcome incidence but had a 6-fold increase in the incidence of acute stent thrombosis.  Death and reinfarction rates were similar.

Source: Thorax
Author(s): HJ Kang, B Hwangbo, G-K Lee, B-H Nam, H-S Lee, MS Kim, JM Lee, JI Z, HS Lee, J-Y Han

This randomized trial included 148 pts with potentially resectable NSLCL.  Mediastinal staging was randomized to EBUS-centered (EBUS possibly followed by EUS) or EUS-centered (EUS possibly followed by EBUS).  Diagnostic accuracy and sensitivity were similar for both groups.  Adding EBUS after initial EUS improved accuracy and sensitivity significantly, whereas adding EUS after initial EBUS did not significantly improve outcomes.  The authors suggest that EBUS is the best first procedure in endoscopic mediastinal staging for potentially resectable lung cancer.

Source: Thorax
Author(s): M Luchtenborg, SP Riaz, E Lim, R Page, DR Baldwin, E Jakobsen, P Vedsted, M Lind, MD Peake, A Mellemgaard, J Spicer, L Lang-Lazdunski, H Moller

Of nearly 360,000 pts in England diagnosed with a first primary lung cancer, outcomes were assessed for 465 patients who underwent resection for small cell cancer.  5-year survival was 45% for resected NSCLC, 31% for resected SCLC, and was 3% for patients who didn't have resection.  Survival was better for patients who had a resection for known SCLC compared to those whose histologic diagnosis wasn't made until after surgery.  The authors conclude that resection should be offered to selected patients with SCLC. 

Source: Journal of the National Cancer Institute
Author(s): Weronica E. Ek, David M. Levine, Mauro D’Amato, Nancy L. Pedersen, Patrik K. E. Magnusson, Francesca Bresso, Lynn E. Onstad, Peter T. Schmidt, Hans Törnblom, Helena Nordenstedt, Yvonne Romero, Wong-Ho Chow, Liam J. Murray, Marilie D. Gammon, Geoffrey Liu, Leslie Bernstein, Alan G. Casson, Harvey A. Risch, Nicholas J. Shaheen, Nigel C. Bird, Brian J. Reid, Douglas A. Corley, Laura J. Hardie, Weimin Ye, Anna H. Wu, Marco Zucchelli, Tim D. Spector, Pirro Hysi, Thomas L. Vaughan, David C. Whiteman, Stuart MacGregor

Gastroesophageal reflux disease is a risk factor for esophageal adenocarcinoma and Barrett’s esophagus. Adenocarcinoma also may develop from Barrett’s esophagus. This multi-institutional study compares genome-wide association data to investigate the genetic architecture of esophageal adenocarcinoma, Barrett’s esophagus and gastroesophageal reflux. A high genetic correlation was found between esophageal adenocarcinoma and Barrett’s esophagus with significant polygenic overlap, which suggest that shared genes underlie the development of both lesions. On the contrary, no statistically significant results were obtained for gastroesophageal reflux.

Source: Journal of the American College of Cardiology
Author(s): Huang G, Schaff HV, Sundt TM, Rahimtoola SH.

In this manuscript the authors propose a strategy for the treatment of obstructive thrombosis of prosthetic heart valves based on a review of 30 studies published over a 17-year period. They suggest indications for thrombolysis and surgery in right and left sided prosthetic heart valve thrombosis.

Source: New England Journal of Medicine
Author(s): O. Fröbert and Others

This randomized controlled trial evaluated routine mural thrombus aspiration followed by PCI to PCI alone in 7,244 pts with STEMI undergoing PCI.  Thrombus aspiration did not significantly decrease mortality, recurrent MI, or stent thrombosis. Stroke and neurologic complication rates were similar between the groups.   

Source: JACC Cardiovascular Interventions
Author(s): Michael Mok; Luis Nombela-Franco; Eric Dumont; Marina Urena; Robert DeLarochellière; Daniel Doyle; Jacques Villeneuve; Mélanie Côté; Henrique B. Ribeiro; Ricardo Allende; Jerôme Laflamme; Hugo DeLarochellière; Louis Laflamme; Ignacio Amat-Santos; Philippe Pibarot; François Maltais; Josep Rodés-Cabau

This study evaluated the effects of COPD on outcomes after TAVI in 319 pts, 30% of whom had COPD. COPD pts had a lower survival rate at 1 yr (71% vs 85%) and experienced less improvement in functional status. Cumulative mortality was predicted by the 6 min walk test, and periprocedural pulmonary complications were predicted by FEV1. TAVI was deemed futile in 40% of COPD pts.